JIVA.AI Teams Up with Aevice Health for Innovative Asthma AI with FDA-Cleared Remote Patient Monitor

06th February, 2024 | By Vrushti Kothari 

Jiva.ai and Aevice Health collaborate to pioneer breakthrough medical AI for asthma adverse event prediction based on Aevice Health’s FDA-cleared remote patient monitor.

Jiva.ai, a leading no-code AI platform, and Aevice Health, a prominent provider of remote respiratory monitoring solutions for the healthcare continuum,  announced their collaboration on a jointly funded co-innovation programme by Innovate UK and Enterprise Singapore aimed at creating a state-of-the-art medical AI to predict asthma exacerbations.

The collaboration represents a synergistic blend of Jiva.ai's cutting-edge AI capabilities and Aevice Health's expertise in developing a proprietary remote patient monitoring platform that empowers individuals to proactively manage their respiratory health. The project will see the development of an AI capable of asthma exacerbation prediction, utilizing Aevice Health’s FDA-cleared AeviceMD, to provide asthma patients with a groundbreaking tool to take charge of their conditions.

Asthma poses a significant global healthcare burden, with billions spent on reactive management only in the advanced stages. Advancements in remote technology has generated extensive data that holds promise for early asthma prediction and management. Similarly, development in AI technology now offers a possibility to creating diagnostic and prognostic tools that could reduce patient suffering, save lives, and cut costs to heathcare systems.

Implementing a “multimodal AI”, the ability to read multiple different types of data to make predictions, within a clinical setting can be complex. Multimodal AI ideally involves adding new predictors to existing AI models, which is desirable but technologically and logistically difficult in healthcare. With the FDA-cleared AeviceMD, biomarkers of interest for asthma exacerbations can be collected unobtrusively and continuously within and outside of clinical settings. The diverse data collected can then be integrated into the multimodal AI to create an early warning system for asthmatic patients to get the care they need before their asthma escalates.

"Combining Jiva.ai's no-code AI platform with Aevice Health’s advanced remote patient monitoring platform is a significant leap forward in the realm of healthcare innovation,” said Dr Manish Patel, CEO at Jiva.ai. “We are excited about the potential impact of this collaboration, as it underscores our commitment to leveraging technology to enhance patient outcomes and improve overall healthcare delivery.”

Aevice Health's CTO, Dr Rex Tan, echoed this sentiment, stating, "Asthma is a global health concern, and our collaboration with Jiva.ai through the Enterprise Singapore and Innovate UK jointly funded co-innovation project aligns with our mission to empower individuals to actively manage their respiratory health.”

This project will leverage the strengths of both companies to develop an intelligent and user-friendly care regime that integrates seamlessly into patients' lives. The collaboration is set to redefine the landscape of respiratory health management, demonstrating the potential of AI-driven solutions in addressing complex healthcare challenges.

The UK-Singapore Collaborative R&D grant call is a programme jointly launched by Innovate UK, part of the UK Research and Innovation, and Enterprise Singapore. The grant’s objective is to fund business-led collaborative research and development (CR&D) projects between the UK and Singapore, focused on industrial research in particular sectors including health and life sciences.

As the project unfolds, Jiva.ai and Aevice Health anticipate not only advancing the frontiers of medical technology but also making substantial contributions to the broader discourse on harnessing AI for proactive healthcare measures.

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer